heterozygous


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

heterozygous

Genetics (of an organism) having different alleles for any one gene

heterozygous

[¦hed·ə·rō¦zī·gəs]
(genetics)
Of or pertaining to a heterozygote.
References in periodicals archive ?
Subsequent beta globin sequencing revealed a heterozygous beta-plus thalassemia mutation, while analysis for alpha globin deletions revealed a heterozygous Southeast Asian (SEA) two-gene deletion, consistent with--/[alpha][alpha] alpha thalassemia minor.
Patients with fatal infantile cardiomyopathy were found to have two missense mutations in AARS2 , homozygous or compound heterozygous, except one case who carried one DNA base pair insertion mutation and a missense mutation.
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.
In case of genotypic distribution at Gln/Glu 27 we found no significant association of nocturnal asthma with heterozygous Gln/Glu polymorphism (OR =1.
35delG mutations was identified in four families and heterozygous c.
Distributions of Mediterranean fever mutations Distribution of Mediterranean fever mutations % E148Q heterozygous 7.
The aim of the current study is to isolate homozygous [alpha]GT KO cells from postnatal heterozygous [alpha]GT KO skin fibroblasts and ultimately to evaluate the developmental competence of isolated homozygote cells after SCNT.
In a previous study, a 22 year old male diagnosed with delayed puberty at 18 years was found to have compound heterozygous GNRHR mutations Gln106Arg and Arg262Gln.
The global pivotal Phase 3 LDL-C lowering efficacy studies of the company's bempedoic acid is undergoing in patients with atherosclerotic cardiovascular disease (ASCVD), heterozygous familial hypercholesterolemia (HeFH) and "statin intolerant" with hypercholesterolemia inadequately treated with current lipid-modifying therapies.
The heterozygous and homozygous states for Hb E are benign conditions clinically, but individuals often have red cell microcytosis and/or hypochromia.
As part of the ODYSSEY programme, alirocumab has been evaluated in ten randomized, double-blind, multinational, phase III, studies either as monotherapy or in combination with other Lipid lowering therapy (LLT), and included patients with heterozygous familial hypercholesterolaemia (HeFH) and non-FH patients who had clinical atherosclerotic cardiovascular disease.